Involvement of OP18 in cell proliferation

• Published in: Biochemical and biophysical research communications Vol. 179; no. 3; p. 1649
• Main Authors: Melhem, R F, Strahler, J R, Hailat, N, Zhu, X X, Hanash, S M
• Format: Journal Article
• Language: English
• Published: United States 30-09-1991
• Subjects: Base Sequence; Cell Differentiation - drug effects; Cell Division; Dimethyl Sulfoxide - pharmacology; Humans; Lymphocyte Activation - drug effects; Lymphocytes - drug effects; Lymphocytes - immunology; Microtubule Proteins; Molecular Sequence Data; Neoplasm Proteins - physiology; Oligonucleotides, Antisense - pharmacology; Phosphoproteins - analysis; Phosphoproteins - genetics; Phosphoproteins - physiology; Protein Biosynthesis - drug effects; RNA, Messenger - genetics; Stathmin; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured
• ISSN: 0006-291X
• DOI: 10.1016/0006-291X(91)91764-4

Op18 is a highly conserved major cytosolic phosphoprotein that is expressed at high levels in acute leukemia and in neuroblastoma. In this study we present evidence pointing to a role for Op18 in cellular proliferation. Blocking of Op18 mRNA translation using antisense oligonucleotides delayed entrance of mitotically stimulated normal peripheral blood lymphocytes into the S phase. Moreover treatment of HL-60 promyelocytic leukemia cells with DMSO or PMA which induced terminal differentiation resulted in a decrease in the level of Op18 RNA and protein. Inhibition of lymphoid proliferation with cyclosporin also resulted in reduced Op18 levels.